CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lipella Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lipella Pharmaceuticals Inc
400 N Lexington St Ste Ll103
Phone: (412) 901-0315p:412 901-0315 PITTSBURGH, PA  15208  United States Ticker: LIPOLIPO
Business Summary
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The Company is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary Jonathan H.Kaufman 58 1/1/2005 1/1/2005
Chief Financial Officer DouglasJohnston 40 11/9/2022 10/1/2021
Chief Medical Officer, Director Micheal B.Chancellor 66 1/1/2008 1/1/2008
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 5 (As of 3/26/2025)
Outstanding Shares: 2,548,811 (As of 3/26/2025)
Shareholders: 15
Stock Exchange: NASD
Fax Number: (302) 658-3694


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025